Group 1 - White Dove Online has made progress in its IPO application in Hong Kong, with the China Securities Regulatory Commission approving its overseas issuance and domestic unlisted shares for full circulation [1] - The company plans to issue no more than 45.05 million overseas listed ordinary shares, with 11 shareholders converting approximately 11.8 million domestic unlisted shares into overseas listed shares [1] - If the IPO is successful, White Dove Online is expected to become the first AI company in the insurance industry [1] Group 2 - The company reported revenues of 405 million yuan, 660 million yuan, 914 million yuan, and 467 million yuan for the years 2022, 2023, 2024, and the first five months of 2025, respectively [1] - Net losses for the same periods were 25.075 million yuan, 17.18 million yuan, 27.712 million yuan, and 18.679 million yuan, totaling cumulative losses of 88.646 million yuan [1] - Revenue growth of 31% was observed in the first five months of 2025, but net losses increased from 3.462 million yuan to 18.679 million yuan, a year-on-year increase of 439.54% [1] Group 3 - White Dove Online's revenue is highly concentrated and relies heavily on traditional commission models, which limits its profitability [2] - The primary sources of income include insurance transaction services, precision marketing, digital solutions, and TPA services, with insurance transaction service revenue increasing from 77.0% in 2022 to 90.3% in 2024 [2] - This indicates that 90% of the company's revenue comes from traditional insurance commission income, despite its branding as an "insurance technology" company [2]

Investment Rating - The report maintains an "Outperform" rating for the biopharmaceutical industry [1] Core Viewpoints - The development of commercial health insurance is supported by favorable policies, with significant potential for capital inflow. Since 2009, policies have continuously supported the establishment of a multi-level medical security system and the development of commercial health insurance. The sharing of medical insurance data with commercial insurance companies is entering a practical phase, which is expected to improve the insurance landscape [2][28] - The commercial health insurance sector is projected to reach a compensation scale of approximately 471.57 billion yuan by 2030 under neutral expectations, indicating substantial potential for the medical industry [31][32] Summary by Sections Part 1: Commercial Health Insurance is Flourishing, Compensation Growth is Expected - The demand side emphasizes the impact of premium pricing and the insurance needs of patients with pre-existing conditions and the elderly. The increase in disposable income and policies allowing the use of personal medical insurance accounts for purchasing health insurance are expected to enhance insurance uptake [11][12][29] - The supply side highlights the importance of product design in health management, special drug coverage, and deductible settings. Enhancements in these areas can attract more policyholders and improve profitability [20][21][28] Part 2: Current Situation: Insufficient Motivation for Innovative Drug and Device Use - The DRG payment system has reduced the motivation for hospitals to use innovative drugs and devices, necessitating the exploration of alternative payment sources. High-level hospitals face greater pressure under the DRG system, which may hinder the adoption of innovative treatments [35][39] Part 3: Commercial Insurance Development Benefits Innovative Drugs and DTP Pharmacies - The commercial health insurance sector is increasingly covering innovative drugs, with payments rising from 1.1 billion yuan in 2020 to 2.2 billion yuan in 2023, reflecting a compound annual growth rate of 27.8%. The penetration rate for commercial health insurance in the innovative drug market remains low, indicating significant room for growth [67][68] - DTP pharmacies are emerging as a crucial channel for the distribution of innovative drugs, providing a pathway for patients to access high-value medications outside of traditional hospital settings [76][80] Part 4: Innovative Devices May Benefit from Commercial Insurance Development - Innovative medical devices, particularly those not fully covered by insurance, are expected to benefit from commercial insurance. The report suggests that high-value medical devices and certain surgical procedures may gain traction in the commercial insurance market [4][81] Part 5: Investment Recommendations - The report recommends focusing on companies with rich pipelines in innovative drugs, such as Heng Rui Medicine and BeiGene, as well as DTP pharmacies and TPA (Third Party Administrator) companies that are well-positioned to benefit from the growth of commercial health insurance [4][81]

本次港股IPO，白鸽在线计划将募资用于技术研发、收购及海外扩张，以进一步增强其技术实力与市场竞争力。其在高投入领域如AI和大数据 分析等方面，短期内可能加剧亏损，投资者对其战略执行效率及资源整合能力也存在疑虑。尽管如此，多轮融资结果显示，市场对白鸽在线在 场景险数字化领域的领先地位和技术实力抱有期待。 制图：佘诗婕 01 增收不增利 根据灼识咨询报告，按2023年收入计，白鸽在线在中国的场景险数字化风险管理解决方案提供商中位列第一，市场份额为4.4%。截至最后实际 可行日期，白鸽在线拥有超过3.02亿份被保险用户资料、68个不同生产及生活场景的数据、超过200000份理赔报告及超过84亿份保单记录。 星标 ★ IPO日报 精彩文章第一时间推送 近日，中国场景险数字化风险管理解决方案的领军企业——白鸽在线（厦门）数字科技股份有限公司（以下简称"白鸽在线"），正式向港 交所提交上市申请，引发市场的广泛关注。 成立于2015年的白鸽在线，在保险科技领域迅速崛起，凭借数据资源与技术优势，不断拓展业务版图，吸引了众多资本的青睐。自2016年起， 公司先后完成五轮融资，展现出强劲的发展势头。然而，公司目前也面临着盈利模式 ...